SCHOLAR-1 demonstrated to poor outcomes in patients with refractory DLBCL supporting a need for more effective therapies for these patients.
SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients.